Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vicplas InternationalSGX:569 3-Year RORE % is 93.75 as of Jan. 2026. The stock has 5 warning signs investors should review. Among 780 Medical Devices & Instruments companies, Vicplas International ranks better than 92.56% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Vicplas International's 3-Year RORE % for the quarter that ended in Jan. 2026 was 93.75%.
The industry rank for Vicplas International's 3-Year RORE % or its related term are showing as below:
SGX:569's 3-Year RORE % is ranked better than 92.56% of 780
companies
in the Medical Devices & Instruments industry
Industry Median: -3.245
vs SGX:569: 93.75
Vicplas International (SGX:569) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Vicplas International 3-Year RORE % Related Terms
Vicplas International 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Vicplas International's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:569 vs ABT, SYK, MDT: 3-Year RORE % Comparison
For the Medical Devices subindustry, Vicplas International's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vicplas International 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vicplas International's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Vicplas International's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jan. 2026 and 3-year before.
Vicplas International (SGX:569) has a 3-Year RORE % of 93.75 as of Jan. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Vicplas International and its competitors. According to the industry distribution chart, Vicplas International ranks #58 out of 780 companies in the Medical Devices & Instruments industry, placing it in the top 7.4%.
Is Vicplas International's 3-Year RORE % too high?
Vicplas International's current 3-Year RORE % is 93.75. Based on the distribution chart, Vicplas International ranks #58 out of 780 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Vicplas International's 3-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vicplas International ranks #58 out of 780 companies for 3-Year RORE %. This places Vicplas International in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Vicplas International and its competitors. Vicplas International's current 3-Year RORE % is 93.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicplas International stock overvalued right now?
Based on GuruFocus' analysis, Vicplas International (SGX:569) is currently considered Possible Value Trap. The stock's GF Value™ is S$0.11, compared to a current price of S$0.07 — trading 36.4% below its estimated fair value. The current 3-Year RORE % is 93.75. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Vicplas International (SGX:569), the current 3-Year RORE % is 93.75 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vicplas International Ltd is an investment holding company. The company is organized into two main business activities: the Pipes and Pipe Fitting segment and the Medical Devices segment, which is the key revenue driver. Pipes and Pipe Fittings segment engages in the manufacturing and distribution of plastic building products, including uPVC pipes and pipe fittings and electrical conduits. The Medical device segment is involved in the research, design, development, and manufacture of medical devices. The company generates majority of its revenue from medical devices. The company does its sales through geographical segments that include Singapore, Malaysia, Mexico, China, and the United Kingdom, of which the majority of the revenue comes from Singapore.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:569 has been successfully added to your 
